![](/img/cover-not-exists.png)
811PCabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A randomized, open label, phase III, multicenter trial
Andrén, O., Widmark, A., Falt, A., Ulvskog, E., Davidsson, S., Thellenberg Karlsson, C., Hjalm-Eriksson, M.Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx370.028
Date:
September, 2017
File:
PDF, 49 KB
english, 2017